NEW YORK (GenomeWeb News) - Illumina said today that it will work with the Children's Hospital of Eastern Ontario to develop molecular tests that would screen infants for spinal muscular atrophy and blood diseases.
 
Under the terms of the agreement, Illumina will hold the commercial rights for any assays it develops with the CHEO, which is located in Ottawa.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.